
Broad Institute studies map age-related shifts in human striatal cells and six molecular zones, offering a research reference rather than a brain-age test.

On November 12, 2026, the Broad Institute reported two studies published in Cell on the molecular organization of the human striatum and how its cell patterns vary with age.
The central aging finding concerns molecular identity: in the Broad team's analysis of more than 130 brains, gene-expression differences between six striatal zones became less distinct with increasing age. Researchers also found age-related changes in cell composition and gene expression across cell types. For longevity research, the contribution is a finer human reference map of aging in a brain structure involved in movement and behavior. Its value lies in describing how cellular patterns differ across adult aging and providing a basis for more focused questions about healthy brain function.
Study model: Humans, using postmortem brain tissue.
The Broad report places the striatum within the basal ganglia, a network involved in movement and behavior. It also describes the striatum's relevance to decision-making and its connections to psychiatric disorders, addiction and neurodegeneration. That makes the region a useful focus for reference mapping across adult aging.
An important feature of this work is that it addresses two related questions. Where are molecularly distinct cells located within the striatum? And how do cell proportions and gene-expression patterns vary between people and across ages? The studies approach those questions with different methods and sample sets.
The spatial study used Slide-tags to analyze more than 1 million cells across striatal tissue from 19 postmortem brains. According to the Broad Institute, the researchers identified six zones whose projection neurons had distinct gene-expression profiles. The result adds a molecular layer to the description of this brain region.
Evan Macosko described this organization as “hidden histology.” In the Broad account, cells that looked alike under a microscope had strong transcriptional differences that were consistent from person to person. Here, a zone means an area distinguished by the gene-expression profiles of its projection neurons.
This distinction matters for interpreting the headline. The reported boundaries refer to differences in molecular profiles across the mapped tissue. The aging result concerns those profiles becoming less distinct, which is the specific observation behind descriptions of boundaries becoming blurred.
Researchers then examined the six-zone pattern in more than 130 brains from the companion study. This linked the spatial map to a larger set of age-related comparisons. The sequence of analyses matters: the initial map and the subsequent aging analysis drew on different sample descriptions.
The companion study used single-nucleus RNA sequencing on 4 million cells from the striatum and prefrontal cortex of nearly 200 adult postmortem brains. Its focus included variation in cell abundance as well as gene expression. Those measurements provide a complementary view to the spatial organization described in the zone study.
According to the Broad report, cell-type proportions varied substantially from person to person. This was especially apparent among non-neuronal cells such as astrocytes and microglia. Proportions were more consistent across different brain tissues within the same individual. The comparison makes variation between people an important part of the reference picture.
The researchers also reported that oligodendrocyte progenitor-cell abundance declined by approximately 40% between ages 30 and 80. Gene-expression patterns changed with age across cell types, especially in projection neurons. These are separate observations: one concerns how abundant a cell type was and the other concerns patterns of gene expression.
For a reader, keeping those measurements separate makes the atlas easier to interpret. A change in cell composition describes the balance of cell types in the analyzed tissue. A change in gene expression describes a different feature of those cells. The studies bring both kinds of information into the same broader reference effort.
The Broad describes the BRAIN Initiative Cell Atlas Network, or BICAN, as a flagship project of the NIH BRAIN Initiative. The striatum studies were part of that larger effort. Nature reported that the broader collection comprised 25.5 million brain cells from humans, macaques and marmosets across 26 papers.
Those figures describe the wider collection rather than the Broad striatum studies alone. According to Nature's coverage, the atlas work combined gene-expression measurements with other cellular features and spatial information. Its scale provides context for the two studies while preserving the distinction between their individual datasets.
Steven Burger said establishing common ranges for cell-type proportions and gene expression provides context for studying disease. The logic is straightforward: a reference range helps researchers frame a comparison. In this case, person-to-person variation and age-associated patterns become part of the background against which disease-related tissue could be examined.
The Broad also reported that data and workflows for both studies were shared openly. That makes the maps material for other researchers to examine and build on. Kiku Ichihara described the atlas work as an initial step and said BICAN would apply its tools and methods beyond the basal ganglia to the rest of the brain.
For healthy-aging research, the most useful question is how these layers of information fit together. A future comparison could ask whether an apparent difference between disease-related tissue and a reference sample reflects age or the cell composition of the tissue being compared. The atlas gives researchers a way to make that question more specific by considering both the location of cells and their molecular profiles.
The practical takeaway is to read the atlas as a framework for research questions. Ask which feature was measured, which samples supplied it and which outcome would make the result relevant to health. This keeps the finding attached to its actual measurements rather than to the broad label of brain aging.
Related context includes separating molecular signals from measured function and tracking the path from aging targets to human outcomes. For personal decisions about neurological symptoms or treatment, qualified clinical care is the appropriate setting.
The next step is to test the six-zone aging pattern in additional human samples and determine whether the molecular differences track measurable changes in brain function.
Turning striatal gene-expression patterns into a personal brain-age score would oversell this atlas. AgeAmaze helps adults who follow longevity research assess claims about biomarkers and emerging interventions through clear scientific explanations, with attention to evidence strength rather than promises about supplements or therapies.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog